Bladder Cancer Clinical Trial

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Summary

This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w)

View Full Description

Full Description

This is a first in human, multicenter, open-label Phase 1-2 study evaluating the safety, tolerability, and initial efficacy of AU-007 with or without aldesleukin, in patients with unresectable locally advanced or metastatic cancer. Patients must either be ineligible for or have progressed on prior standard of care therapy. Phase 1 consists of 3 escalation Arms, each starting with a single 1+2 escalation cohort followed by 3+3 escalation cohorts to define the recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD). The study begins in Arm A evaluating escalating doses of AU-007 (Q2w) in sequential escalation cohorts to define the recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD). In Arm B, AU-007 (Q2w) is evaluated in combination with a single dose of aldesleukin given with the first AU-007 dose. AU-007 is administered at a fixed dose (Q2w) with an escalating single aldesleukin dose in sequential escalation cohorts. In Arm C, AU-007 is evaluated in combination with aldesleukin both given Q2w. AU-007 will be administered at a fixed dose with an escalating dose of aldesleukin in each sequential Arm C escalation cohort. The Phase 2, cohort expansion portion of the study consists of three expansion Arms evaluating the initial efficacy of the RP2D from corresponding dose escalation Arms A, B, and C in selected solid tumor types. Initially, melanoma and renal cell cancer will be evaluated in each Arm. Other eligible cancers include but not limited to Merkel Cell Carcinoma, non-small cell lung cancer and urothelial cancer.

View Eligibility Criteria

Eligibility Criteria

Selected Inclusion Criteria:

Measurable or non-measurable disease as per RECIST v1.1 criteria and documented by CT and/or MRI. In Cohort Expansion, patients with truly non-measurable only disease (e.g., ascites, pleural or pericardial effusion, organomegaly), are not eligible for enrolment.
In Dose Escalation patients must have selected tumor types and have progressed after standard of care treatment, or be intolerant to treatment, or refused standard treatment
Female patients of childbearing potential must have a negative serum or urine pregnancy test performed within 72 hours prior to the initiation of study drug administration. Female patients of childbearing potential must be willing to use two forms of contraception throughout the study, starting with Screening through 60 days after the last dose of AU-007. Abstinence is acceptable if this is the established and the preferred contraception method for the patient
Male patients with partners of childbearing potential must use barrier contraception from the time of consent through 60 days after discontinuation of AU-007 and must not donate sperm during this period. In addition, male patients should have their partners use contraception (as documented for female patients) for the same period of time
Patients who have previously received an immune checkpoint inhibitor (e.g., anti-PD-L1, anti-PD-1, anti-CTLA-4) prior to enrollment must have checkpoint inhibitor immune-related toxicity resolved to either Grade ≤ 1 or baseline (prior to the checkpoint inhibitor) to be eligible for enrollment. Patients who experienced previous checkpoint inhibitor-related hypothyroidism are eligible for the study regardless of CTCAE grade resolution if well controlled on thyroid hormone replacement therapy

Symptomatic central nervous system (CNS) metastases must have been treated, be asymptomatic for ≥ 14 days, and meet the following at the time of enrollment:

No concurrent treatment for CNS disease (e.g., surgery, radiation, corticosteroids ≥ 10 mg prednisone/day or equivalent)
No concurrent leptomeningeal disease or cord compression

Exclusion Criteria:

Patients with a history of known autoimmune disease with exceptions of

Vitiligo
Psoriasis, atopic dermatitis, or other autoimmune skin condition not requiring systemic treatment
History of Graves' disease in patients now euthyroid for > 4 weeks
Hypothyroidism managed by thyroid hormone replacement
Alopecia
Arthritis managed without systemic therapy beyond oral nonsteroidal anti- inflammatory drugs
Major surgery or traumatic injury within 8 weeks before first dose of AU-007
Unhealed wounds from surgery or injury
Treatment with > 10 mg per day of prednisone (or equivalent) or other immune-suppressive drugs within the 7 days prior to the initiation of study drug. Steroids for topical, ophthalmic, inhaled, or nasal administration are allowed

Prior anti-cancer therapy before the planned start of AU-007 as follows:

Not recovered to baseline from toxicity of prior systemic cancer therapy(ies).
Not recovered from toxicity of radiotherapy.
Concurrent use of hormones either to maintain castrate levels of testosterone in patients with castration-sensitive prostate cancer or for non-cancer-related conditions (e.g., insulin for diabetes, hormone replacement therapy) is acceptable. Bisphosphonates are permitted.
Patients who have experienced SAEs during prior IL-2 therapy (including but not limited to bowel perforation, GI bleeding, arrythmias, MI, repetitive seizures).
Inflammatory process that has not resolved for ≥ 4 weeks from the date of first study dose. Patients with chronic low-grade inflammatory processes such as radiation-induced pneumonitis are excluded regardless of duration
Second primary invasive malignancy not in remission for ≥ 1 year. Exceptions include non-melanoma locally advanced skin cancer, cervical carcinoma in situ, localized prostate cancer (Gleason score ≤ 7), resected melanoma in situ, or any malignancy considered to be indolent and never required therapy, with the exception of indolent lymphomas

Study is for people with:

Bladder Cancer

Phase:

Phase 1

Estimated Enrollment:

69

Study ID:

NCT05267626

Recruitment Status:

Recruiting

Sponsor:

Aulos Bioscience, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 9 Locations for this study

See Locations Near You

Sylvester Comprehensive Cancer Center
Miami Florida, 33136, United States More Info
Leonel Hernandez Aya
Contact
305-243-6606
[email protected]
START South Texas Accelerated Research Therapeutics
Grand Rapids Michigan, 49503, United States More Info
Drew Rasco
Contact
210-593-5265
[email protected]
Carolina Biooncology Institute
Huntersville North Carolina, 28078, United States More Info
John Powderly, MD
Contact
704-947-6599
[email protected]
Tennessee Oncology
Nashville Tennessee, 37203, United States More Info
Meredith McKean
Contact
615-329-7274
[email protected]
Southside Cancer Care Centre
Miranda New South Wales, 2228, Australia More Info
Paul DeSouza
Contact
+61(02) 95539588
[email protected]
Monash Health
Clayton Victoria, 3168, Australia More Info
Sophia Frentzas
Contact
+61(03) 8572 2392
[email protected]
Austin Health
Heidelberg Victoria, 3084, Australia More Info
Andrew Weickhardt
Contact
+61(03) 9496 9918
[email protected]
The Alfred Hospital
Melbourne Victoria, 3004, Australia More Info
Andrew Haydon, MD
Contact
+61390766963
[email protected]
Sunshine Hospital
Saint Albans Victoria, 3021, Australia More Info
Catherine Oakman
Contact
+61383456666
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Phase:

Phase 1

Estimated Enrollment:

69

Study ID:

NCT05267626

Recruitment Status:

Recruiting

Sponsor:


Aulos Bioscience, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.